Medical condition
Early Breast Cancer
Early Breast Cancer is a medical condition tracked by NovaPharmaNews across 7 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- docetaxel (DOCETAXEL ACCORD) Antineoplastic and immunomodulating agents (L01)
- pertuzumab (PERJETA) Antineoplastic and immunomodulating agents (L01)
- abemaciclib (VERZENIO) Antineoplastic and immunomodulating agents (L01)
- ribociclib (KISQALI) Antineoplastic and immunomodulating agents (L01)
- trastuzumab (HERZUMA) Antineoplastic and immunomodulating agents (L01)
- olaparib (LYNPARZA) Antineoplastic and immunomodulating agents (L01)
- trastuzumab emtansine (KADCYLA) Antineoplastic and immunomodulating agents (L01)
Latest Early Breast Cancer news
Enhertu's Dual FDA Approvals: A Game Changer in Early Breast Cancer Treatment
Daiichi and AstraZeneca's Enhertu has received dual FDA approvals for early breast cancer, marking a significant milestone in oncology. This article explores the implications for investors and pharma teams.
FDA Grants Dual Approval for T-DXd in HER2+ Early Breast Cancer
The FDA has granted dual approval for T-DXd in treating HER2+ early breast cancer, marking a significant advancement in oncology. This decision has crucial implications for pharmaceutical stakeholders.